ESMOLOL HYDROCHLORIDE

Electrolyte / Mineral

Brand names: Esmolol Hydrochloride

Intravenous

Mechanism of Action

12.1 Mechanism of Action Esmolol hydrochloride injection is a beta 1 -selective (cardioselective) adrenergic receptor blocking agent with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane stabilizing activity at therapeutic dosages. Its elimination half-life after intravenous infusion is approximately 9 minutes. Esmolol hydrochloride injection inhibits the beta 1 receptors located chiefly in cardiac muscle, but this preferential effect is not absolute and at higher doses it begins to inhibit beta 2 receptors located chiefly in the bronchial and vascular musculature.

Indications

postoperative

in the physician’s judgment

during surgery

on emergence from anesthesia and in the postoperative period

when in the physician’s judgment such specific intervention is considered indicated. Use of esmolol hydrochloride injection to prevent such events is not recommended.

Contraindications

• verapamil) and esmolol hydrochloride injection in close proximity (i.e.
• while cardiac effects from the other are still present)
• including anaphylaxis
• 7 ) Pulmonary hypertension ( 4 ) Known hypersensitivity to esmolol ( 4 )

FDA Warnings

5 WARNINGS AND PRECAUTIONS • Risk of hypotension, bradycardia, and cardiac failure: Monitor for signs and symptoms of cardiovascular adverse effects
10 ) • Risk of exacerbating reactive airway disease ( 5
6 ) • Risk of unopposed alpha-agonism and severe hypertension in untreated pheochromocytoma ( 5
9 ) • Risk of myocardial ischemia when abruptly discontinued in patients with coronary artery disease ( 5

Known Side Effects

4 documented side effects by frequency

Drug Not Working

>10%

Low Blood Pressure

1-10%

High Blood Pressure

0.1-1%

Condition Worsened

0.1-1%

Community Discussions

No community discussions found for ESMOLOL HYDROCHLORIDE yet.

Compare With

0 available comparisons

No comparisons yet.

Formulations

Dosage Forms

Tablet

Route

Intravenous